|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
June 2005FeaturesCover Story Payers’ Costly Battle Against CancerWith better drugs, many cancers are becoming chronic diseases necessitating costly maintenance, and insurers are scrambling for ways to control their expenditures. Early efforts to rein in costs are being met with stiff resistance from oncologists, however. Industry Will Combinatorial Chemistry Keep its Promise?Once the hottest of new technologies, this didn’t live up to its initial promise. Now, biotechs are refining the science to develop targeted libraries and important new therapies. Formularies Expect P&T Committees to Demand More DataRecent withdrawals of popular therapies will have multiple effects. At managed care plans, formulary committees are likely to demand more postmarketing data before embracing the next breakthrough. Clinical Biotech Takes on The Obesity ChallengeBig pharma’s search for effective obesity treatments has proven harder than expected. Biotech is eager to step into the breach with new ideas. Business Starting a Biotech Company in a Dot.Com WorldAn entrepreneur shares lessons from his arduous search for attention from a VC crowd that was far more interested in dot.com startups than biotechs.
Leading Edge The Future of Gene TherapyBe patient and it will come, say some of the nation’s top experts in this once-promising field. Early hype was followed by setbacks – but with a cautious approach, this could become a staple of 21st century medicine. DepartmentsOpeners Not Your Father’s $6 Million ManA new Steve Austin... so what? Editorial Reviewing the ReviewsDavid B. Nash, MD, MBA, assesses the state of systematic reviews. Discourse The New Emphasis on SafetyWhat’s behind the FDA’s new emphasis on safety? Drugs and Diagnostics New Vaccine-Making Technology Shot in Arm for IndustryGenetic engineering gives birth to improved vaccine-making technology. Biotech Business Pharmacogenomics: Answer to Biotech’s Problems?Pharmacogenomics is driving essential changes in drug development. In the Pipeline Number of Monoclonal Antibodies on Market Nearly Doubles by 2008The Tufts Center for the Study of Drug Development projects that by 2008, the U.S. Food and Drug Administration is likely to approve 11 of the current mAb products in the pipeline. |
|||||